Sweeney J D, Petrucci J, Yankee R
Miriam Hospital, Providence, RI 02906, USA.
Transfus Sci. 1997 Dec;18(4):575-83. doi: 10.1016/s0955-3886(97)00056-8.
For almost two decades, two types of platelet products have been available: pooled random donor platelets (RDP), manufactured from whole blood donations and single donor platelets (SDP), manufactured on apheresis devices. During this period, two trends have occurred--an overall increase in demand for platelets and a preference for the use of SDP. The reasons for the disproportionate increase in the use of SDP relates in all likelihood to supply logistics, perceptions of quality, lack of price sensitivity on the part of prescribing physicians, and minimizing donor exposures in an era of uncertainty and litigation surrounding the allogeneic blood supply. In the cost-conscious 1990s, it is essential to reappraise the situation and perform a critical analysis of the relative value of these products. Such an analysis leads to an inescapable conclusion that preferential use of RDP is the more logical strategy.
在近二十年里，一直有两种类型的血小板制品可供使用：混合随机供体血小板（RDP），由全血捐献制备而成；单采血小板（SDP），通过血液成分单采设备制备而成。在此期间，出现了两种趋势——对血小板的总体需求增加以及对使用SDP的偏好。SDP使用量不成比例增加的原因很可能与供应物流、质量认知、开处方医生缺乏价格敏感性以及在围绕异体血供应存在不确定性和诉讼的时代尽量减少供体暴露有关。在注重成本的20世纪90年代，重新评估这种情况并对这些产品的相对价值进行批判性分析至关重要。这样的分析得出一个不可避免的结论，即优先使用RDP是更符合逻辑的策略。
